A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors

Dan Zhou(Sichuan Agricultural University), Andrew J. Sonderfan(Synta Pharmaceuticals (United States)), Noriaki Tatsuta(Synta Pharmaceuticals (United States)), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Richard C. Bates(Synta Pharmaceuticals (United States)), Takayo Inoue(Synta Pharmaceuticals (United States)), Yuan Liu(Sichuan University), Weiwen Ying(Synta Pharmaceuticals (United States)), Yumiko Wada(University of Tsukuba), Josephine Ye(Synta Pharmaceuticals (United States)), Keizo Koya(Synta Pharmaceuticals (United States)), Luisa Shin Ogawa(Synta Pharmaceuticals (United States))
Toxicology and Applied Pharmacology
September 30, 2013
10.1016/j.taap.2013.09.018
Cited by 74

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.
|Journal of Biological Chemistry|1993|375
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362
Immunohistochemical localization of the D1 dopamine receptor in rat brain reveals its axonal transport, pre- and postsynaptic localization, and prevalence in the basal ganglia, limbic system, and thalamic reticular nucleus.
|Proceedings of the National Academy of Sciences|1992|260